news
-
6 July 2021Sequana Medical’s results from RED DESERT alfapump DSR® study presented as one of the Highlights at Heart Failure 2021 Online Congress
Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that the positive results from its RED DESERT study of alfapump DSR® (Direct Sodium Removal) which were presented at the Heart Failure 2021 Online Congress as part of the Late Breaking Science Results were also selected for the congress’ Highlights session, held virtually on 1 July 2021.
Dr. Jeffrey Testani, Associate Professor of Medicine and Director of Heart Failure Research at Yale University School of Medicine, commented: “It was an honour to present the results from the RED DESERT study at the Heart Failure 2021 Online Congress and to be included in the Highlights session. It is encouraging to see this recognition and we are thankful to the congress team. This elegant and innovative therapeutic approach of alfapump DSR therapy demonstrated a significant improvement of cardio-renal function and a dramatic and sustained improvement in diuretic response.”
alfapump DSR is Sequana Medical’s proprietary therapy being developed for the treatment of diuretic-resistant congestion in heart failure patients. Strong results from the RED DESERT study in eight patients with diuretic-resistant heart failure were reported in May 2021, demonstrating that repeated alfapump DSR therapy could effectively replace patients’ high dose loop diuretics and restore their diuretic response and overall cardio-renal status.
Related
Sequana Medical announces first patient enrolled in SAHARA DESERT
Sequana Medical announces 2020 Full Year Results and 2021 Outlook
Sequana Medical announces granting of key alfapump DSR® patents in U.S. and Europe
Sequana Medical announces H1 2020 results and provides business update
Sequana Medical announces €7.3 million debt financing and provides clinical update
Sequana Medical announces 2019 Full Year Results and 2020 Outlook
Sequana Medical announces new share capital amount and new number of shares
Sequana Medical announces 2019 Half Year Results and Year-to-date Business Update
Sequana Medical appoints leading experts as Heart Failure Scientific Advisors
Sequana Medical to host webcast on 27 May 2019
Sequana Medical announces 2018 Full Year Results and 2019 Outlook
Sequana Medical raises €27.5 million in successful Initial Public Offering
Sequana Medical Announces Publication of Results of Multicentre Randomized Controlled Study
Sequana Medical Announces Results of the MOSAIC trial data presented at 2017 AASLD
Sequana Medical Announces Sudden Passing of Founder, President & CEO
Ian Crosbie Joins Sequana Medical as Chief Financial Officer
Sequana Medical has been selected as a finalist for the 2012 MEDTEC EMDT Innovation Awards
Sequana Medical receives CE Mark Approval for the ALFApumpTM System and adds key executive to team
NovaShunt announces the launch of its new corporate identity: Sequana Medical